
    
      The study enrols patients from four different NHL subtypes: FL, DLBCL, MCL and other indolent
      NHL. The study will employ a two-stage design where the decision to further enrol any NHL
      subtype in stage 2 will depend on best responses after two or three cycles in stage 1.
    
  